Our Services
Medical Information
Helpful Resources
Published on: 7/15/2026
Finasteride and Prostate Cancer Detection: What to Know
Finasteride lowers prostate-specific antigen (PSA) levels by roughly 50%, which can make prostate cancer harder to detect through standard PSA screening. However, finasteride does not hide or mask the cancer itself—the disease remains visible through biopsy, imaging, and adjusted PSA interpretation. Doctors typically double PSA readings in patients taking finasteride to maintain screening accuracy.
Key points:
If you're taking finasteride or noticing urinary changes, understanding your symptoms is the critical first step. A free, instant, online symptom check can help you evaluate what you're experiencing, identify possible causes, and clarify whether you should speak with a doctor. It takes only a few minutes, requires no signup, and gives you personalized insights—empowering you to make informed decisions about your next steps.
Reviewed for medical accuracy: 07/15/2026
Not seeing your question? No worries.
Submit your own QuestionFinasteride is a medication that can lower PSA levels in the blood. PSA is a substance made by the prostate, and doctors use its levels to help detect prostate cancer. When someone takes finasteride, their PSA levels might be lower than they would be otherwise. This can make it more challenging to spot changes that could indicate prostate cancer.
Key Points:
In summary, while finasteride affects PSA levels, it does not prevent the detection of prostate cancer if doctors adjust their interpretation of the test results accordingly. If you're experiencing symptoms or have concerns about your prostate health, you can start by taking a free symptom assessment to better understand your condition.
(References)
Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, & Thompson IM. (2005). Long-term effects of finasteride on prostate specific antigen .... The Journal of urology, 16093979.
Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, et al. (1997). Biologic variability of prostate-specific antigen and its .... Urology, 9218012.
Irani J. (2008). [PCPT trial: expected bias and their management]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 18455083.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.